Get the Stockscreener App
1.37
1.44%
-0.02
Cyclerion Therapeutics Inc stock is traded at $1.37, with a volume of 63,045.
It is down -1.44% in the last 24 hours and up +26.85% over the past month.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.
See More
Previous Close:
$1.39
Open:
$1.32
24h Volume:
63,045
Relative Volume:
0.05
Market Cap:
$5.37M
Revenue:
$556.00K
Net Income/Loss:
$-5.28M
P/E Ratio:
-0.6402
EPS:
-2.14
Net Cash Flow:
$-6.23M
1W Performance:
+4.58%
1M Performance:
+26.85%
6M Performance:
-38.16%
1Y Performance:
-43.39%
1-Day Range:
$1.31
$1.4999
1-Week Range:
$1.275
$1.4999
52-Week Range:
$1.0266
$3.79
Cyclerion Therapeutics Inc Stock (CYCN) Company Profile
Name
Cyclerion Therapeutics Inc
Sector
Industry
Phone
617-621-7722
Address
301 BINNEY STREET, CAMBRIDGE, MA
Compare CYCN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYCN
Cyclerion Therapeutics Inc
|
1.4108 | 5.29M | 556.00K | -5.28M | -6.23M | -2.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.38 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
763.30 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
722.15 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.25 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
291.85 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cyclerion Therapeutics Inc Stock (CYCN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-21 | Initiated | Truist | Buy |
| Sep-24-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-03-19 | Initiated | Credit Suisse | Neutral |
Cyclerion Therapeutics Inc Stock (CYCN) Latest News
CYCN Earnings History & Surprises | EPS & Revenue Results | CYCLERION THERAPEUTICS INC (NASDAQ:CYCN) - ChartMill
CYCN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Cyclerion Therapeutics (CYCN) to Release Earnings on Tuesday - Defense World
CYCN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Cyclerion Therapeutics Inc expected to post a loss of 38 cents a shareEarnings Preview - TradingView
Cyclerion Therapeutics (CYCN) Price Target Increased by 100.00% to 8.16 - Nasdaq
CYCN: Positive Feedback from FDA Sets Stage for Phase 2 Trial of CYC-126 in 2H26 - Research Tree
Tech Rally: Is Cyclerion Therapeutics Inc stock a good pick for beginnersJuly 2025 Final Week & Community Consensus Trade Signals - baoquankhu1.vn
Is Cyclerion Therapeutics Inc. stock a good pick for beginnersJuly 2025 Update & High Conviction Buy Zone Alerts - mfd.ru
Mobix Labs and Peraso Engage in Talks for Possible Acquisition - Intellectia AI
Volatility Watch: Can Cyclerion Therapeutics Inc deliver alphaWall Street Watch & Entry Point Confirmation Alerts - baoquankhu1.vn
Cyclerion receives FDA feedback on depression treatment development - Investing.com Nigeria
Cyclerion To Advance CYC-126 Into Phase 2 Study For Treatment-resistant Depression - Nasdaq
Cyclerion Gains FDA Support for CYC-126 Depression Study - TipRanks
Cyclerion Therapeutics announces progress toward Cyc-126 phase 2 proof-of-concept study with FDA feedback - marketscreener.com
Cyclerion Therapeutics Announces Progress Toward CYC-126 - GlobeNewswire
Is Cyclerion Therapeutics Inc. a cyclical or defensive stockPrice Action & Scalable Portfolio Growth Ideas - mfd.ru
CYCN Technical Analysis & Stock Price Forecast - Intellectia AI
Can Cyclerion Therapeutics Inc. deliver alphaWeekly Earnings Recap & Capital Efficiency Focused Strategies - mfd.ru
Aug PreEarnings: What is the target price for Cyclerion Therapeutics Inc stockAnalyst Upgrade & Free Accurate Trade Setup Notifications - baoquankhu1.vn
Brokers Offer Predictions for CYCN FY2025 Earnings - Defense World
CYCN Should I Buy - Intellectia AI
Profit Recap: What is Cyclerion Therapeutics Incs market position2025 Market Outlook & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Investor Mood: Why is Hello Group Inc Depositary Receipt stock going downJuly 2025 Weekly Recap & Target Return Focused Picks - baoquankhu1.vn
Top Penny Stocks To Follow NowJanuary 6th - MarketBeat
Weekly Earnings: Is Cyclerion Therapeutics Inc attractive for institutional investorsWatch List & Consistent Return Investment Signals - baoquankhu1.vn
Is Cyclerion Therapeutics Inc. stock a safe buy before earningsJuly 2025 Momentum & AI Based Buy and Sell Signals - Улправда
Rockford Register Star: Local News, Politics & Sports in Rockford, IL - FinancialContent
Why Cyclerion Therapeutics Inc. stock could rally in 2025Rate Hike & Real-Time Buy Zone Alerts - Улправда
Why retail investors favor Cyclerion Therapeutics Inc. stockTreasury Yields & Daily Entry Point Trade Alerts - Улправда
Top Penny Stocks To Follow Now – January 6th - Defense World
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Will Cyclerion Therapeutics Inc. stock benefit from upcoming earnings reports2026 world cup usa national team round of 32 playmakers high defensive line expert forecast expert opinion - ulpravda.ru
Cyclerion Therapeutics, Inc. (CYCN) Discusses Medsteer Development Collaboration and Updates on Phase 2 Proof-of-Concept Study in Treatment-Resistant DepressionSlideshow (NASDAQ:CYCN) 2026-01-07 - Seeking Alpha
Exciting Surge in Cyclerion: What’s Next? - StocksToTrade
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Cyclerion Therapeutics Collaboration Sparks Curiosity - timothysykes.com
Cyclerion, Medsteer form strategic anesthetic technology alliance - TipRanks
Cyclerion Therapeutics stock jumps in premarket after Medsteer deal — what CYCN investors watch next - TechStock²
Stay updated with the stocks that are on the move in today's pre-market session. - Chartmill
Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression - Sahm
Morning Market Movers: CYCN, AZI, AEVA, OS See Big Swings - RTTNews
Cyclerion (CYCN) Enters Exclusive Collaboration with Medsteer to Advance CYC-126 Clinical Trials - Intellectia AI
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Cyclerion partners with Medsteer to advance depression treatment platform By Investing.com - Investing.com Nigeria
Cyclerion Expands Partnership With Medsteer; Plans Phase 2 Trial Of CYC-126 In 2H 2026; Stock Up - Nasdaq
Why Cyclerion Therapeutics Shares Are Trading Higher By 44%; Here Are 20 Stocks Moving Premarket - Benzinga
Critical Review: Cyclerion Therapeutics (NASDAQ:CYCN) & BeyondSpring (NASDAQ:BYSI) - Defense World
Cyclerion Therapeutics Inc. (CYCN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Cyclerion announces strategic agreement with Medsteer - marketscreener.com
Cyclerion Therapeutics Inc Stock (CYCN) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.07%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):